Physix Frontier badgePhysix Frontier
PublishChinese | EN

Physix Frontier · News Briefing Card (TMTPost · Sep 21, 2026)

Anew Labs' First Drug AN5162 Labeled 'Me-Too'

KEY FACTS

  • ByteDance spinoff Anew Labs secured $290 million in funding, setting a record for AI drug discovery.
  • Its first self-developed drug, AN5162, is an IL-17 inhibitor that structurally mimics competitors like Eli Lilly.
  • Public patent data indicates AN5162's activity metrics do not surpass rivals such as Ascletis and InnoCare.
  • Although the company built a closed loop of five major models, its initial pipeline remains a traditional me-too strategy.

KEY DATA

$290 millionFunding Amount
<100nMIC50 Threshold

PHYSIX OBSERVATION

Amid capital frenzy, AI drug discovery faces a misalignment between instrumental rationality and commercial reality. Despite possessing a top-tier model matrix, Anew Labs' debut remains low-level repetition. This warns the industry that while algorithms can accelerate screening, they cannot automatically bridge the innovation gap from me-too to best-in-class. Relying solely on distilled data without biological insight risks turning AI into expensive automated outsourcing rather than a disruptor.

Source: TMTPost report